High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib
Crossref DOI link: https://doi.org/10.1007/s13277-015-3660-3
Published Online: 2015-06-19
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fiala, Ondrej
Pesek, Milos
Finek, Jindrich
Topolcan, Ondrej
Racek, Jaroslav
Minarik, Marek
Benesova, Lucie
Bortlicek, Zbynek
Poprach, Alexandr
Buchler, Tomas
Text and Data Mining valid from 2015-06-19